BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11220654)

  • 1. Endogenous hormone metabolism as an exposure marker in breast cancer chemoprevention studies.
    Kaaks R
    IARC Sci Publ; 2001; 154():149-62. PubMed ID: 11220654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.
    Kendall A; Dowsett M
    Endocr Relat Cancer; 2006 Sep; 13(3):827-37. PubMed ID: 16954432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of various progestogens on metabolic risk factors for breast cancer.
    Campagnoli C; Abbà C; Ambroggio S; Lotano MR; Peris C
    Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():22-31. PubMed ID: 17943536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Energy balance, physical activity, and cancer risk.
    Fair AM; Montgomery K
    Methods Mol Biol; 2009; 472():57-88. PubMed ID: 19107429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential clinical applications of insulin-like growth factor-1 ligand in human breast cancer.
    Chong YM; Subramanian A; Sharma AK; Mokbel K
    Anticancer Res; 2007; 27(3B):1617-24. PubMed ID: 17595785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joint effect of insulin-like growth factors and sex steroids on breast cancer risk.
    Yu H; Shu XO; Li BD; Dai Q; Gao YT; Jin F; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2003 Oct; 12(10):1067-73. PubMed ID: 14578144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study.
    Kahán Z; Gardi J; Nyári T; Földesi I; Hajnal-Papp R; Ormándi K; Lázár G; Thurzó L; Schally AV
    Int J Oncol; 2006 Jul; 29(1):193-200. PubMed ID: 16773200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
    Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
    J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Breakthrough in breast cancer chemoprevention].
    Kahán Z; Thurzó L
    Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fasting glucose is a risk factor for breast cancer: a prospective study.
    Muti P; Quattrin T; Grant BJ; Krogh V; Micheli A; Schünemann HJ; Ram M; Freudenheim JL; Sieri S; Trevisan M; Berrino F
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1361-8. PubMed ID: 12433712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
    Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
    Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cord serum estrogens, androgens, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 in Chinese and U.S. Caucasian neonates.
    Troisi R; Lagiou P; Trichopoulos D; Xu B; Chie L; Stanczyk FZ; Potischman N; Adami HO; Hoover RN; Hsieh CC
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):224-31. PubMed ID: 18199728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.
    Fabian CJ; Kimler BF; Zalles CM; Khan QJ; Mayo MS; Phillips TA; Simonsen M; Metheny T; Petroff BK
    Breast Cancer Res Treat; 2007 Nov; 106(1):75-84. PubMed ID: 17221152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
    Krajcik RA; Borofsky ND; Massardo S; Orentreich N
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer.
    Eng-Wong J; Hursting SD; Venzon D; Perkins SN; Zujewski JA
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1468-73. PubMed ID: 14693739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of breast cancer.
    Castrellon AB; Glück S
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):443-52. PubMed ID: 18366291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.
    Johansson H; Baglietto L; Guerrieri-Gonzaga A; Bonanni B; Mariette F; Macis D; Serrano D; Sandri MT; Decensi A
    Breast Cancer Res Treat; 2004 Nov; 88(1):63-73. PubMed ID: 15538047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis.
    Pasanisi P; Venturelli E; Morelli D; Fontana L; Secreto G; Berrino F
    Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1719-22. PubMed ID: 18628423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.
    Baglietto L; English DR; Hopper JL; Morris HA; Tilley WD; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):763-8. PubMed ID: 17416768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pill and the breast.
    Drife JO
    IPPF Med Bull; 1984 Dec; 18(6):1-2. PubMed ID: 12313402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.